City

Cambridge (1)

Guangzhou (1)

London (1)

Rochester (1)

Shanghai (1)

Overall Status

Recruiting (2)

Terminated (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Creative Biosciences (Guangzhou) Co., Ltd. (1)

Fudan University (1)

Polaris Group (1)

Collaborator

Guangzhou Xiangkang Medical Research Co., Ltd. (1)

Intervention

adi-peg 20 (1)

camrelizumab combined with apatinib (1)

chest ct or pathological examination (1)

diagnostic test: sputum dna methylation analysis (1)

Study Documents

Intervention Type

drug (2)

diagnostic test (1)

procedure (1)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (2)

Observational (1)

sarcomatoid carcinoma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Sputum DNA Testing for Lung Cancer in China

Recruiting

Lung Cancer
+15 more

Diagnostic Test: Sputum DNA methylation analysis
chest CT or pathological examination

Guangzhou, Guangdong, China

Nanfang Hospital of Southern Medccal University

Dec 29, 2022

PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma Trial in Shanghai (Camrelizumab Combined With Apatinib)

Recruiting

PD-1 Immunotherapy
+3 more

Camrelizumab Combined With Apatinib

Shanghai, Shanghai, China

Fudan University Shanghai Cancer Center

Mar 1, 2022

Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma

Terminated

Pleural Mesothelioma Malignant Advanced
+6 more

ADI-PEG 20

Rochester, Minnesota
+3 more

Sep 24, 2020